Ansa Biotechnologies Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ansa Biotechnologies Inc.
During Q2, biopharmas brought in an aggregate $12.5bn in financing and device company fundraising totaled $3.7bn; while in vitro diagnostic firms and research tools players raised $720m.
Private Company Edition: In other venture capital mega-rounds, Aurion brought in $120m, Sionna launched with $111m and Irish firm Renexxion said a private equity group committed up to $100m in total investment to be made within 36 months of a future public listing.
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
- Synthesis Technologies, Production Processes
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.